Cross-protective immune responses elicited by live attenuated influenza vaccines

Yo Han Jang, Baik Lin Seong

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.

Original languageEnglish
Pages (from-to)271-282
Number of pages12
JournalYonsei medical journal
Volume54
Issue number2
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Attenuated Vaccines
Influenza Vaccines
Cross Protection
Inactivated Vaccines
Pandemics
Human Influenza
Immunity
Hemagglutinins
Neuraminidase
Surface Antigens
Infection
Neutralizing Antibodies
Autoimmunity
Vaccination
Vaccines
Animal Models
Guidelines
Antigens

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{655d9105504f4f5c83ac9c5facd309a0,
title = "Cross-protective immune responses elicited by live attenuated influenza vaccines",
abstract = "The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.",
author = "Jang, {Yo Han} and Seong, {Baik Lin}",
year = "2013",
month = "3",
day = "1",
doi = "10.3349/ymj.2013.54.2.271",
language = "English",
volume = "54",
pages = "271--282",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Cross-protective immune responses elicited by live attenuated influenza vaccines. / Jang, Yo Han; Seong, Baik Lin.

In: Yonsei medical journal, Vol. 54, No. 2, 01.03.2013, p. 271-282.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cross-protective immune responses elicited by live attenuated influenza vaccines

AU - Jang, Yo Han

AU - Seong, Baik Lin

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.

AB - The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.

UR - http://www.scopus.com/inward/record.url?scp=84873254941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873254941&partnerID=8YFLogxK

U2 - 10.3349/ymj.2013.54.2.271

DO - 10.3349/ymj.2013.54.2.271

M3 - Review article

C2 - 23364956

AN - SCOPUS:84873254941

VL - 54

SP - 271

EP - 282

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -